(MENAFN- The Peninsula) Bloomberg
Nigeria has appointed Aliko Dangote, Africa's richest man, to lead a committee commissioned with eliminating malaria in the West African nation as the mosquito-borne infection has made a comeback across the continent amid disruptions related to the coronavirus pandemic.
Africa's most populous nation, which also has the highest prevalence of malaria globally, can save 687 billion naira ($1.6 billion) this year, and 2 trillion naira by 2030, if it were to put an end to the disease, President Muhammadu Buhari said on Tuesday.
Dangote, with a net worth of about $19.6 billion according to the Bloomberg Billionaires Index, was picked to lead an anti-malaria committee of 16 people. The decision was based on his previous support of 'various health issues such as polio and primary health care system strengthening,” the president said in an emailed statement.
While the prevalence of the illness in Nigeria has been cut to 27% from 42% in 2010, the country still accounts for almost a third of the world's malaria deaths.
Read Also
- Nigeria's NNPC renews oil contracts to produce 10 billion barrels
- Extra polio shot offered to London children as concern grows
- WHO moves to roll out first malaria vaccine in Africa
A 'significant funding gap” is preventing the nation from stamping out malaria, Minister of Health Osagie Ehanire said. Nigeria needs about 1.89 trillion naira to reduce malaria's pervasiveness and mortality by 2025, Ehanire said.
Malaria killed almost half a million African children in 2020, with most being under the age of five, and the World Health Organization last month urged countries across the continent to apply for part of the $160 million in funding for the first vaccine for malaria.
Folorunsho Alakija, who made her money from oil, has also been selected for the committee. Other members include Tony Elumelu, a Nigerian billionaire who owns investment firm Heirs Holdings, and Herbert Wigwe, the chief executive officer of Access Bank Plc, the country's biggest lender.
MENAFN17082022000063011010ID1104709331
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.